Close Menu

NEW YORK (GenomeWeb) – Quidel reported after the close of the market Thursday that its second quarter revenues rose 5 percent year over year due primarily to growth in the firm's rapid immunoassay business. Growth in molecular and specialized diagnostic solutions also contributed to a lesser extent.

The San Diego-based diagnostics company reported total sales of $108.3 million, up from $103.2 million in the second quarter of 2018 and in line with analysts' consensus estimate.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.